Tag: support

Sydney, Australia, June 07, 2026 (GLOBE NEWSWIRE) -- With annual inflation at 4.6% in the year to March 2026 and roughly 4.4 million Australians now aged 65 and over, retirees face a sharpening challenge: turning a lifetime of savings into income that keeps pace with the rising cost of groceries, fuel and everyday essentials. The pressure is compounded by longevity, with many Australians spending two or even three decades in retirement, and by a shift in mindset that retirement itself demands. In the accumulation years, investors can ride out market volatility and recover losses over time; in the drawdown phase, with shorter horizons and less capacity to recoup losses, the priority moves to predictable income and preserving purchasing power. To learn more visit https://termplus.com.au/insights-news/news/turning-savings-into-reliable-monthly-income-in-retirement/

Ramat Gan, Israel, June 07, 2026 (GLOBE NEWSWIRE) -- Odysight.ai^® (NASDAQ/TASE: ODYS) today announced that, as part of a planned step to expand the Company’s financing toolkit in the U.S. capital market, it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC) under which it may offer and sell from time to time and at its discretion shares of its common stock having an aggregate offering price of up to $20 million pursuant to an At-The-Market (ATM) program with the investment bank Roth Capital Partners. The program provides the Company with an additional, flexible financing infrastructure that can be utilized at the Company’s discretion to support business development and capitalize on market opportunities.

A former CIA and Pentagon advisor says Trump is weeks away from unlocking the largest untapped mineral deposit in the United States

Initiates voluntary prepackaged Chapter 11 process to implement Restructuring Transactions that have the support of 100% of its lenders, over 60% of the holders of GoHealth, Inc. Class A Common Stock, and over 99% of the holders of GoHealth Holdings, LLC interests.

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association^®, held in New Orleans, Louisiana from June 5-8, 2026.

New sliced-to-order flavors deliver comforting tradition and vibrant, globally inspired taste